Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera <sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trialYuankai Shi, Yanan Ji, Xiaonan Hong et al.|Hematological Oncology|2022Cited by 9